{
  "id": 17162545,
  "title": "Aspen Neuroscience prices IPO at $15 per share",
  "url": "https://urgent.news/2026/10/30/aspen-neuroscience-prices-ipo-at-15-per-share",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T02:16:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/aspen-neuroscience-prices-ipo-at-15-per-share-93CH-4985728"
  },
  "original_language": "en",
  "account": "Aspen Neuroscience, a San Diego-based biotech firm working on therapies for Parkinson's disease, has priced its IPO at $15 per share. The company aims to raise about $140.6 million through the sale of 9.375 million shares. Underwriters have the option to purchase an additional 1.406 million shares at the same price, less fees. The stock is set to trade on the Nasdaq Global Select Market under the symbol ASPE, beginning today. The offering is slated to close on November 2, 2026, pending usual closing conditions. Aspen Neuroscience is focused on developing cell therapies using induced pluripotent stem cells, with its main candidate being a single-dose, autologous iPSC-based treatment for Parkinson's disease. The company's registration statement with the SEC went live on October 29, 2026.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M",
        "url": "https://urgent.news/2026/10/30/aspen-neuroscience-lands-141m-ipo-while-bambusa-secures-169m",
        "published": "2026-10-30T06:11:31.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}